MariTidevsMazdutide

MariTide (maridebart cafraglutide) is a peptide-antibody conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody. This dual GLP-1 agonist + GIP antagonist mechanism is distinctive — most competing dual incretin drugs (tirzepatide, CT-388, VK2735) activate both receptors. The rationale for GIP antagonism is based on genetic and pharmacological evidence that loss-of-function in GIP signalling is associated with reduced obesity, suggesting that blocking rather than activating GIP may produce superior weight-loss outcomes.

The GLP-1 agonist component drives the established appetite-suppression and glycemic-control effects of the incretin pathway. The GIP receptor antagonist antibody simultaneously blocks GIP signalling at adipocytes and centrally, which preclinical data suggest enhances energy expenditure, reduces lipid storage, and amplifies the weight-loss effect of GLP-1 receptor activation. Whether GIP agonism (as in tirzepatide) or GIP antagonism (as in MariTide) is superior remains an open question that Phase 3 head-to-head data may eventually resolve.

The antibody-conjugated structure produces an exceptional pharmacokinetic profile, with a half-life of approximately three weeks. This supports once-monthly subcutaneous dosing — a unique practical advantage over the once-weekly schedules of all other late-stage obesity drugs. Phase 2 results showed roughly 20% body weight loss at 52 weeks. Animal studies have also suggested slower weight regain after discontinuation than seen with shorter-acting GLP-1 agonists, possibly due to the prolonged drug exposure during the washout period. Phase 3 MARITIME trials launched in 2026 will define the molecule's clinical positioning.

Mazdutide is a dual-receptor agonist that activates both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure. The GLP-1 component functions similarly to other GLP-1 agonists — binding to receptors in the hypothalamus to reduce hunger, stimulating glucose-dependent insulin secretion from pancreatic beta cells, and slowing gastric motility to prolong post-meal satiety.

The glucagon receptor component distinguishes mazdutide from pure GLP-1 agonists. Glucagon binding in the liver activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates key enzymes in fatty acid oxidation and ketogenesis. This drives the liver to burn stored fat as fuel rather than accumulate it — a mechanism with direct therapeutic relevance for patients with metabolic-associated fatty liver disease (MAFLD). In adipose tissue, glucagon signaling promotes lipolysis and may activate thermogenic programs in brown and beige fat cells.

The engineering challenge in dual GLP-1/glucagon agonists is balancing the hyperglycemic effect of glucagon against the glucose-lowering effects of GLP-1. Mazdutide achieves this by tuning the relative receptor affinities so that GLP-1-mediated insulin secretion offsets glucagon-driven glucose production, resulting in net glycemic improvement alongside enhanced fat oxidation and energy expenditure.